{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:08:07Z","timestamp":1792728487930,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Buprenorphine treatment of opioid use disorder (OUD) is safe and effective, but opioid withdrawal during treatment initiation is associated with poor retention in care. As fentanyl has replaced heroin in the drug supply, case reports and surveys have indicated increased concern for buprenorphine-precipitated withdrawal (PW); however, some observational studies have found a low incidence of PW.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate buprenorphine PW incidence and assess factors associated with PW among emergency department (ED) or hospitalized patients.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study at 3 academic hospitals in Philadelphia, Pennsylvania, included adults with OUD who underwent traditional or high-dose buprenorphine initiation between January 1, 2020, and December 31, 2021. Exclusion criteria included low-dose buprenorphine initiation and missing documentation of opioid withdrawal severity within 4 hours of receiving buprenorphine.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Buprenorphine initiation with an initial dose of at least 2 mg of sublingual buprenorphine after a Clinical Opiate Withdrawal Scale (COWS) score of 8 or higher. Additional exposures included 4 predefined factors potentially associated with PW: severity of opioid withdrawal before buprenorphine (COWS score of 8-12 vs \u226513), initial buprenorphine dose (2 vs 4 or \u22658 mg), body mass index (BMI) (&amp;lt;25 vs 25 to &amp;lt;30 or \u226530; calculated as weight in kilograms divided by height in meters squared), and urine fentanyl concentration (0 to &amp;lt;20 vs 20 to &amp;lt;200 or \u2265200 ng\/mL).<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>The main outcome was PW incidence, defined as a 5-point or greater increase in COWS score from immediately before to within 4 hours after buprenorphine initiation. Logistic regression was used to estimate the odds of PW associated with the 4 aforementioned predefined factors.<\/jats:p><\/jats:sec>Results<\/jats:title>The cohort included 226 patients (150 [66.4%] male; mean [SD] age, 38.6 [10.8] years). Overall, 26 patients (11.5%) met criteria for PW. Among patients with PW, median change in COWS score was 9 points (IQR, 6-13 points). Of 123 patients with confirmed fentanyl use, 20 (16.3%) had PW. In unadjusted and adjusted models, BMI of 30 or greater compared with less than 25 (adjusted odds ratio [AOR], 5.12; 95% CI, 1.31-19.92) and urine fentanyl concentration of 200 ng\/mL or greater compared with less than 20 ng\/mL (AOR, 8.37; 95% CI, 1.60-43.89) were associated with PW.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this retrospective cohort study, 11.5% of patients developed PW after buprenorphine initiation in ED or hospital settings. Future studies should confirm the rate of PW and assess whether bioaccumulated fentanyl is a risk factor for PW.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.35895","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:30:54Z","timestamp":1727451054000},"page":"e2435895","source":"Crossref","is-referenced-by-count":51,"title":["Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl"],"prefix":"10.1001","volume":"7","author":[{"given":"Ashish P.","family":"Thakrar","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"},{"name":"Center for Addiction Medicine and Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Christine","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Siaw-Asamoah","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Spadaro","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Faude","sequence":"additional","affiliation":[{"name":"Emergency Medicine Residency, NYU Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Snider","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kit","family":"Delgado","sequence":"additional","affiliation":[{"name":"Center for Addiction Medicine and Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"},{"name":"Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lowenstein","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"},{"name":"Center for Addiction Medicine and Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Kampman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanmarie","family":"Perrone","sequence":"additional","affiliation":[{"name":"Center for Addiction Medicine and Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"},{"name":"Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin S.","family":"Kilaru","sequence":"additional","affiliation":[{"name":"Center for Addiction Medicine and Policy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"},{"name":"Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"2","key":"zoi241063r1","article-title":"Buprenorphine for managing opioid withdrawal.","volume":"2","author":"Gowing","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2S","key":"zoi241063r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 focused update.","volume":"14","author":"American Society of Addiction Medicine","year":"2020","journal-title":"J Addict Med"},{"issue":"2","key":"zoi241063r4","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right.","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi241063r5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jsat.2010.04.001","article-title":"Factors associated with complicated buprenorphine inductions.","volume":"39","author":"Whitley","year":"2010","journal-title":"J Subst Abuse Treat"},{"key":"zoi241063r6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl.","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi241063r7","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl.","volume":"16","author":"Varshneya","year":"2022","journal-title":"J Addict Med"},{"issue":"6","key":"zoi241063r8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/15563650.2022.2032730","article-title":"Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl.","volume":"60","author":"Spadaro","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"zoi241063r9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era.","volume":"16","author":"Sue","year":"2022","journal-title":"J Addict Med"},{"issue":"8","key":"zoi241063r10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/acem.14507","article-title":"\u201cJust give them a choice\u201d: patients\u2019 perspectives on starting medications for opioid use disorder in the ED.","volume":"29","author":"Schoenfeld","year":"2022","journal-title":"Acad Emerg Med"},{"issue":"1","key":"zoi241063r11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ajad.13069","article-title":"Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone.","volume":"30","author":"Antoine","year":"2021","journal-title":"Am J Addict"},{"issue":"2","key":"zoi241063r12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/dar.13394","article-title":"Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: a case series.","volume":"41","author":"Shearer","year":"2022","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"zoi241063r13","article-title":"Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: a case series.","volume":"4","author":"Spadaro","year":"2023","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"zoi241063r14","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108147","article-title":"Protracted renal clearance of fentanyl in persons with opioid use disorder.","volume":"214","author":"Huhn","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi241063r15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/add.16100","article-title":"Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance.","volume":"118","author":"Luba","year":"2023","journal-title":"Addiction"},{"issue":"4","key":"zoi241063r16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ADM.0000000000001155","article-title":"Association of urine fentanyl concentration with severity of opioid withdrawal among patients presenting to the emergency department.","volume":"17","author":"Thakrar","year":"2023","journal-title":"J Addict Med"},{"issue":"6","key":"zoi241063r17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids.","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"zoi241063r18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","article-title":"Low dose initiation of buprenorphine: a narrative review and practical approach.","volume":"16","author":"Cohen","year":"2022","journal-title":"J Addict Med"},{"issue":"3","key":"zoi241063r19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.6108","article-title":"Incidence of precipitated withdrawal during a multisite emergency department-initiated buprenorphine clinical trial in the era of fentanyl.","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi241063r20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1572","article-title":"High-dose buprenorphine initiation in the emergency department among patients using fentanyl and other opioids.","volume":"6","author":"Snyder","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi241063r25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi241063r26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.annemergmed.2021.10.012","article-title":"Sustained implementation of a multicomponent strategy to increase emergency department-initiated interventions for opioid use disorder.","volume":"79","author":"Lowenstein","year":"2022","journal-title":"Ann Emerg Med"},{"issue":"7","key":"zoi241063r27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.20702","article-title":"Extended-release 7-day injectable buprenorphine for patients with minimal to mild opioid withdrawal.","volume":"7","author":"D\u2019Onofrio","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi241063r28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"2-3","key":"zoi241063r30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.drugalcdep.2007.04.006","article-title":"Sublingual buprenorphine\/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.","volume":"90","author":"Rosado","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"zoi241063r31","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1141980","article-title":"Operational definition of precipitated opioid withdrawal.","volume":"14","author":"Dunn","year":"2023","journal-title":"Front Psychiatry"},{"issue":"10329","key":"zoi241063r32","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(22)00176-3","article-title":"Disparity in the selection of patients in clinical trials.","volume":"399","author":"Habibzadeh","year":"2022","journal-title":"Lancet"},{"issue":"26","key":"zoi241063r33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","article-title":"Illicitly manufactured fentanyl-involved overdose deaths with detected xylazine\u2014United States, January 2019-June 2022.","volume":"72","author":"Kariisa","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi241063r34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi241063r35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1017\/S146114570700836X","article-title":"Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study.","volume":"11","author":"Soyka","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"zoi241063r36","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/ADM.0000000000000997","article-title":"Escalation of opioid withdrawal frequency and subsequent AMA rates in hospitalized patients from 2017 to 2020.","volume":"16","author":"Horton","year":"2022","journal-title":"J Addict Med"},{"issue":"23","key":"zoi241063r37","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1001\/jama.2023.21288","article-title":"Trends in before medically advised discharges for patients with opioid use disorder, 2016-2020.","volume":"330","author":"Thakrar","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"zoi241063r38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment.","volume":"36","author":"Netherland","year":"2009","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"zoi241063r39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/ADM.0000000000001185","article-title":"Fentanyl absorption, distribution, metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl.","volume":"17","author":"Bird","year":"2023","journal-title":"J Addict Med"},{"issue":"1","key":"zoi241063r41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12954-024-00998-9","article-title":"Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study.","volume":"21","author":"Jones","year":"2024","journal-title":"Harm Reduct J"},{"issue":"18","key":"zoi241063r43","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMp2308525","article-title":"Scaling up point-of-care fentanyl testing\u2014a step forward.","volume":"389","author":"Barnett","year":"2023","journal-title":"N Engl J Med"},{"key":"zoi241063r44","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109610","article-title":"Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples.","volume":"240","author":"Park","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zoi241063r45","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A neuropharmacological model to explain buprenorphine induction challenges.","volume":"80","author":"Greenwald","year":"2022","journal-title":"Ann Emerg Med"},{"issue":"3","key":"zoi241063r46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/FTD.0000000000000029","article-title":"Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period.","volume":"36","author":"Tanaka","year":"2014","journal-title":"Ther Drug Monit"},{"key":"zoi241063r3","year":"2019"},{"key":"zoi241063r21","unstructured":"Center for Forensic Science Research & Education. Drug supply assessment: Q1 2021. Drug Checking Quarterly Report. Accessed November 6, 2023. https:\/\/www.cfsre.org\/images\/content\/reports\/drug_checking\/2021-Q1_Drug-Supply-Assessment_Philadelphia.pdf"},{"key":"zoi241063r22","unstructured":"Center for Forensic Science Research & Education. Drug supply assessment: Q2 2021. Drug Checking Quarterly Report. Accessed November 6, 2023. https:\/\/www.cfsre.org\/images\/content\/reports\/drug_checking\/2021-Q2_Drug-Supply-Assessment_Philadelphia.pdf"},{"key":"zoi241063r23","unstructured":"Center for Forensic Science Research & Education. Drug supply assessment: Q3 2021. Drug Checking Quarterly Report. Accessed November 6, 2023. https:\/\/www.cfsre.org\/images\/content\/reports\/drug_checking\/2021-Q3_Drug-Supply-Assessment_Philadelphia.pdf"},{"key":"zoi241063r24","unstructured":"Center for Forensic Science Research & Education. Drug supply assessment: Q4 2021. Drug Checking Quarterly Report. Accessed November 6, 2023. https:\/\/www.cfsre.org\/images\/content\/reports\/drug_checking\/2021-Q4_Drug-Supply-Assessment_Philadelphia.pdf"},{"key":"zoi241063r29","unstructured":"Substance Abuse and Mental Health Services Administration. Buprenorphine quick start guide. June 2021. Accessed August 19, 2024. https:\/\/www.samhsa.gov\/sites\/default\/files\/quick-start-guide.pdf"},{"key":"zoi241063r40","unstructured":"Center for Forensic Science Research & Education. Drug supply assessment: Q1 & Q2 2023. Drug Checking Quarterly Report. Accessed August 19, 2024. https:\/\/www.cfsre.org\/images\/content\/reports\/drug_checking\/2023_Q1_and_Q2_Drug_Checking_Quarterly_Report_CFSRE_NPS_Discovery.pdf"},{"key":"zoi241063r42","doi-asserted-by":"crossref","unstructured":"Sjostedt D. Why is fentanyl drastically cheaper in San Francisco than in LA, NYC and Philly? San Francisco Standard. January 22, 2024. Accessed April 9, 2024. https:\/\/sfstandard.com\/2024\/01\/22\/cheap-street-fentanyl-san-francisco\/","DOI":"10.24148\/wp2024-22"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824168\/thakrar_2024_oi_241063_1726850157.50452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T20:25:00Z","timestamp":1732825500000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.35895","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}